TW200605906A - Remedy for thrombopenia - Google Patents

Remedy for thrombopenia

Info

Publication number
TW200605906A
TW200605906A TW094113923A TW94113923A TW200605906A TW 200605906 A TW200605906 A TW 200605906A TW 094113923 A TW094113923 A TW 094113923A TW 94113923 A TW94113923 A TW 94113923A TW 200605906 A TW200605906 A TW 200605906A
Authority
TW
Taiwan
Prior art keywords
antihuman
activity
antibody
vb22b
found out
Prior art date
Application number
TW094113923A
Other languages
Chinese (zh)
Inventor
Masayuki Tsuchiya
Tetsuro Orita
Yoshihiro Matsumoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of TW200605906A publication Critical patent/TW200605906A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Abstract

By obtaining and purifying antihuman Mp1 antibody, antihuman Mpl sv(Fv)2 is purified with the use of a genetic engineering technique. Further, antihuman Mp1 sc(FV)2 is successfully humanized. By evaluating the TPO-like agonistic activity of sc(Fv)2, it is found out that sc(Fv)2 shows a high agonistic activity to antihuman Mp1 antibody and the activity is comparable or even superior to the activity of human TPO which is a natural ligand. It is also found out that VB22B sc(Fv)2 and humanized VB22B sc(Fv)2 have an effect of increasing platelets in vivo.
TW094113923A 2004-05-11 2005-04-29 Remedy for thrombopenia TW200605906A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004141618 2004-05-11

Publications (1)

Publication Number Publication Date
TW200605906A true TW200605906A (en) 2006-02-16

Family

ID=35320039

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094113923A TW200605906A (en) 2004-05-11 2005-04-29 Remedy for thrombopenia

Country Status (3)

Country Link
JP (1) JPWO2005107784A1 (en)
TW (1) TW200605906A (en)
WO (1) WO2005107784A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
JP5057967B2 (en) 2005-03-31 2012-10-24 中外製薬株式会社 sc (Fv) 2 structural isomer
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
KR101367544B1 (en) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
CA2611726C (en) * 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
US20100040600A1 (en) 2006-06-14 2010-02-18 Chugai Seiyaku Kabushiki Kaisha Agents for Promoting the Growth of Hematopoietic Stem Cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
WO2014186982A1 (en) * 2013-05-24 2014-11-27 昆明圣火药业（集团）有限公司 Use of dencichine in preparation of drug for treating thrombocytopenia
PT3050896T (en) 2013-09-27 2021-08-24 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09289892A (en) * 1996-04-25 1997-11-11 Yamanouchi Pharmaceut Co Ltd C-mpl ligand agonist antibody
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2424371A1 (en) * 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Agonistic monoclonal antibody fragments
WO2002033072A1 (en) * 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Degraded tpo agonist antibody
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity

Also Published As

Publication number Publication date
WO2005107784A1 (en) 2005-11-17
JPWO2005107784A1 (en) 2008-03-21

Similar Documents

Publication Publication Date Title
TW200605906A (en) Remedy for thrombopenia
BRPI0720462A2 (en) ABRASIVE COMPACTS WITH IMPROVED MACHINABILITY
HK1090064A1 (en) Aglycosyl anti-cd154(cd40 ligand) antibodies and uses thereof
NZ595225A (en) Use of tnf inhibitor for treatment of erosive polyarthritis
BRPI0417077A (en) anti-mpl antibodies
CY1112277T1 (en) HUMANIZED ANTI-β7 COMPETITORS AND THEIR USES
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
SG155205A1 (en) Interleukin-10 antibodies
WO2004072266A3 (en) Antibody affinity engineering by serial epitope-guided complementarity replacement
TW200509892A (en) Novel aminobenzophenone compounds
WO2007008712A8 (en) Anti-alpha v beta 6 antibodies and uses thereof
DK1755634T3 (en) Oligopeptides to decrease elevated blood urea concentration
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MY145073A (en) Anti-glypican 3 antibody
ATE518952T1 (en) BISPECIFIC ANTIBODY AS A REPLACEMENT FOR FACTOR VIII
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
EP1461081A4 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
EA201070596A1 (en) HUMANIZED ANTIBODIES AGAINST TL1A
AR054233A1 (en) IGG2 ANTIBODY COMPOSITIONS
ATE483009T1 (en) USE OF HYDROPHOBINS FOR THE DIRT-REPELLENT TREATMENT OF HARD SURFACES
DK2143795T3 (en) Anti-CD20 monoclonal antibody
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
EA200701390A1 (en) METHOD FOR OBTAINING EASY-ACCESSIBLE CELL MATERIAL FROM UMBILICAL BLOOD AND A COMPOSITION BASED ON IT
EP1446157A4 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
WO2004108766A3 (en) Anti-hgf-r antibodies and their use